This company has been marked as potentially delisted and may not be actively trading. Tenzing Acquisition (TZAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TZAC vs. AEON, MTNB, NRBO, AEZS, VAXX, GRAY, CPHI, SPRB, OGEN, and ORGSShould you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include AEON Biopharma (AEON), Matinas Biopharma (MTNB), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), Vaxxinity (VAXX), Graybug Vision (GRAY), China Pharma (CPHI), Spruce Biosciences (SPRB), Oragenics (OGEN), and Orgenesis (ORGS). Tenzing Acquisition vs. Its Competitors AEON Biopharma Matinas Biopharma NeuroBo Pharmaceuticals Aeterna Zentaris Vaxxinity Graybug Vision China Pharma Spruce Biosciences Oragenics Orgenesis Tenzing Acquisition (NASDAQ:TZAC) and AEON Biopharma (NASDAQ:AEON) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Is TZAC or AEON more profitable? AEON Biopharma's return on equity of 0.00% beat Tenzing Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Tenzing AcquisitionN/A -13.32% -1.36% AEON Biopharma N/A N/A -994.63% Does the media prefer TZAC or AEON? In the previous week, AEON Biopharma had 3 more articles in the media than Tenzing Acquisition. MarketBeat recorded 3 mentions for AEON Biopharma and 0 mentions for Tenzing Acquisition. AEON Biopharma's average media sentiment score of 0.66 beat Tenzing Acquisition's score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Tenzing Acquisition Neutral AEON Biopharma Positive Do institutionals & insiders believe in TZAC or AEON? 60.9% of Tenzing Acquisition shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 37.5% of Tenzing Acquisition shares are owned by company insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend TZAC or AEON? AEON Biopharma has a consensus price target of $360.00, indicating a potential upside of 46,053.85%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe AEON Biopharma is more favorable than Tenzing Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenzing Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, TZAC or AEON? Tenzing Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Which has higher earnings and valuation, TZAC or AEON? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenzing AcquisitionN/AN/A$620KN/AN/AAEON BiopharmaN/AN/A-$36.63M-$6.08-0.13 SummaryAEON Biopharma beats Tenzing Acquisition on 7 of the 11 factors compared between the two stocks. Get Tenzing Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TZAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TZAC vs. The Competition Export to ExcelMetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$2.27M$736.37M$2.39B$10.14BDividend YieldN/A4.84%13.79%4.60%P/E RatioN/A1.1725.4025.98Price / SalesN/A26.6412,660.08181.13Price / Cash143.1019.5660.0160.44Price / Book0.456.683.166.29Net Income$620K-$4.13M-$445.27M$271.07M Tenzing Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TZACTenzing AcquisitionN/A$0.44-0.2%N/A-60.5%$2.27MN/A0.00N/AHigh Trading VolumeAEONAEON Biopharma3.1463 of 5 stars$0.76-6.3%$360.00+47,330.8%-98.5%$8.84MN/A4.225News CoverageShort Interest ↓Gap UpMTNBMatinas Biopharma0.1268 of 5 stars$1.66-9.1%N/AN/A$8.44MN/A-0.3430Negative NewsShort Interest ↑Gap DownNRBONeuroBo PharmaceuticalsN/A$0.67+5.1%N/A-80.7%$5.77MN/A0.0010Gap UpHigh Trading VolumeAEZSAeterna ZentarisN/A$3.08+1.3%N/A-23.6%$5.52M$2.37M-0.2120VAXXVaxxinityN/A$0.04-7.0%N/A-95.0%$5.07MN/A-0.0990Gap DownGRAYGraybug VisionN/A$3.22+3.9%N/A-23.8%$5.06MN/A-1.8627Gap UpHigh Trading VolumeCPHIChina PharmaN/A$1.46+0.3%N/A-92.1%$4.75M$4.40M0.00250News CoverageNegative NewsSPRBSpruce Biosciences1.8679 of 5 stars$8.15+9.0%$131.25+1,510.4%-64.5%$4.58M$4.91M-8.6720Gap UpOGENOragenics0.1059 of 5 stars$1.03-4.2%N/A-92.4%$4.25MN/A-0.155Short Interest ↑ORGSOrgenesisN/A$0.78+417.0%N/AN/A$3.72M$662K0.00150Gap Up Related Companies and Tools Related Companies AEON Biopharma Competitors Matinas Biopharma Competitors NeuroBo Pharmaceuticals Competitors Aeterna Zentaris Competitors Vaxxinity Competitors Graybug Vision Competitors China Pharma Competitors Spruce Biosciences Competitors Oragenics Competitors Orgenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TZAC) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenzing Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenzing Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TZAC Stock Alerts